- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02909062
Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy.
August 24, 2020 updated by: Memorial Sloan Kettering Cancer Center
Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy
Electronic activity monitoring (EAM) devices are wearable electronic devices that monitor functional activity and provide personal feedback on activity progression.
This study aims to determine if EAM can provide an objective, assessment of patient functional activity.
The study will also examine the change in functional activity experienced by patients during the first cycle of chemotherapy.
Another objective of the study will be to see if baseline functional activity and the change in functional activity that occurs during the first cycle of chemotherapy can be used to predict patient tolerability of subsequent cycles of chemotherapy.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
54
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Cancer Center
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Rockville Centre, New York, United States
- Memorial Sloan Kettering Rockville Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
MSK clinic
Description
Inclusion Criteria:
- Clinical diagnosis of gastrointestinal malignancy.
- Age ≥ 18 years
- Planned to receive systemic chemotherapy, either adjuvant chemotherapy, or neoadjuvant chemotherapy, or any new line of chemotherapy in the setting of advanced disease. Subjects may enroll prior to chemotherapy or during the first cycle of treatment.
Exclusion Criteria:
- Restricted mobility defined as dependence or anytime use of a walker or wheelchair in the past three months.
- Refusing systemic chemotherapy.
- Concurrent radiotherapy with chemotherapy
- Have received at least one cycle of chemotherapy in the current chemotherapy regimen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Electronic Activity Monitoring (EAM)
This is a prospective, observational study.
The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy.
Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
|
All registered patients will receive a wearable EAM device that will measure their physical activity.
Patients will wear this device around their wrist for the designated period of assessment.
The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed.
For the purpose of this study the EAM data captured will focus on daily step count.
Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device.
The questionnaire was designed specifically for the purpose of this study.
It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device.
The daily questionnaires will be optional; however each participant will be encouraged to complete them.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
EAM Max Step-count On-Chemotherapy - EAM Max Step-count Pre-Chemotherapy
Time Frame: 1 year
|
change in physical activity between pre-chemotherapy and on-chemotherapy by counting the steps
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Armin Shahrokni, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2016
Primary Completion (Actual)
August 21, 2020
Study Completion (Actual)
August 21, 2020
Study Registration Dates
First Submitted
September 19, 2016
First Submitted That Met QC Criteria
September 19, 2016
First Posted (Estimate)
September 21, 2016
Study Record Updates
Last Update Posted (Actual)
August 25, 2020
Last Update Submitted That Met QC Criteria
August 24, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Cancer
-
Five Prime Therapeutics, Inc.CompletedGastric Cancer | Gastrointestinal Cancer | Gastrointestinal Cancer MetastaticUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Dartmouth-Hitchcock Medical Center; West Virginia... and other collaboratorsCompletedGynecologic Cancer | Thoracic Cancer | Gastrointestinal Cancer | Other CancerUnited States
-
Royal Marsden NHS Foundation TrustMerck KGaA, Darmstadt, Germany; 4SC AGUnknownCancer | GI CancerUnited Kingdom
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtRecruitingGastrointestinal Cancer MetastaticNetherlands
-
University Medical Center GroningenCompleted
-
Bristol-Myers SquibbCompletedUpper Gastrointestinal CancerCanada
-
Sumitomo Pharma America, Inc.CompletedAdvanced Gastrointestinal CancerUnited States, Canada
-
Goethe UniversityAgaplesion Markus Krankenhaus gGmbHCompletedAdvanced Gastrointestinal CancerGermany
-
Yonsei UniversitySmall and Medium Business AdministrationCompletedUpper Gastrointestinal CancerKorea, Republic of
-
Boehringer IngelheimCompletedGastrointestinal Cancer, MetastaticBelgium, United States, France, Japan, China
Clinical Trials on Electronic Activity Monitoring (EAM)
-
The University of Texas Medical Branch, GalvestonAmerican Heart AssociationCompleted
-
Taipei Veterans General Hospital, TaiwanRecruitingRespiratory Sounds | General Anesthesia | Intraoperative MonitoringTaiwan
-
Jennifer BramenNational Institutes of Health (NIH); National Institute on Aging (NIA)TerminatedAmnestic Mild Cognitive ImpairmentUnited States
-
Imperial College LondonAsthma UKCompletedAsthma in ChildrenUnited Kingdom
-
Rachel Vreeman, MD, MSBrown University; Moi UniversityCompletedTreatment Failure | Viral ResistanceKenya
-
Massachusetts General HospitalWithdrawnGastrointestinal Cancer
-
University of California, San FranciscoCompletedMultiple SclerosisUnited States
-
Qian ChuRecruitingLung Cancer | Chemoradiotherapy | Patient-Reported Outcomes (PRO)China
-
Harvard Pilgrim Health CareUnknownChronic Kidney Disease | Medication AdherenceUnited States
-
Myant Medical Corp.Partners in Advanced Cardiac EvaluationRecruiting